18F-fluoro-deoxy-glucose positron emission tomography (18F-FDG-PET) visualizes follicular lymphoma irrespective of grading

Annals of Oncology

Volumn 17, Issue 5, 2006, Pages 780-784

  Wohrer S ^a   Jaeger, U ^a   Kletter, K ^a   Becherer, A ^a   Hauswirth, A ^a   Turetschek, K ^a   Raderer, M ^a   Hoffmann, Martha ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

18F FDG PET; Follicular lymphoma; Grading; Staging

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUORODEOXYGLUCOSE F 18; PREDNISOLONE; RITUXIMAB; VINCRISTINE;

ADULT; ARTICLE; BONE MARROW BIOPSY; CANCER GRADING; CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; ECHOGRAPHY; FEMALE; FOLLICULAR LYMPHOMA; FOLLOW UP; HUMAN; INTERMETHOD COMPARISON; LABORATORY DIAGNOSIS; MAJOR CLINICAL STUDY; MALE; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PRIORITY JOURNAL; RELIABILITY; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; WORLD HEALTH ORGANIZATION;

EID: 33646181100     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdl014     Document Type: Article

References (13)

1. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. Blood 1997; 89: 3909-3918.
2. Nathwani BN, Harris NL, Weisenburger DD. Follicular Lymphoma. In Jaffe ES; Harris NL, Stein H, Vardiman JW (eds): World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopietic and Lymphoid Tissues. Lyon: IARC Press 2001; 162-167.
3. Ott G, Katzenberger T, Lohr A et al. Cytomorphologic, immunohistochemical, and cytogenetic profiles of follicular lymphoma: 2 types of follicular lymphoma grade 3. Blood 2002; 99: 3806-3812.
4. Salles G, Herbrecht R, Tilly H et al. Aggressive primary gastrointestinal lymphomas: Review of 91 patients treated with the LNH-84 regimen. A study of the Groupe d'Etude des Lymphomes Agressifs. Am J Med 1991; 90: 77-84.
5. Cheson BD, Horning SJ, Coiffier B et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999; 17: 1244.
6. Kumar R, Maillard I, Schuster SJ, Alavi A. Utility of fluorodeoxyglucose-PET imaging in the management of patients with Hodgkin's and non-Hodgkin's lymphomas. Radiol Clin North Am 2004; 42: 1083-100, viii.
7. Spaepen K, Stroobants S, Dupont P et al. Can positron emission tomography with [(18)F]-fluorodeoxyglucose after first-line treatment distinguish Hodgkin's disease patients who need additional therapy from others in whom additional therapy would mean avoidable toxicity? Br J Haematol 2001; 115: 272-278.
8. Naumann R, Vaic A, Beuthien-Baumann B et al. Prognostic value of positron emission tomography in the evaluation of post-treatment residual mass in patients with Hodgkin's disease and non-Hodgkin's lymphoma. Br J Haematol 2001; 115: 793-800.
9. Czernin J. Clinical applications of FDG-PET in oncology. Acta Med Austriaca 2002; 29: 162-170.
10. Jerusalem G, Beguin Y, Najjar F et al. Positron emission tomography (PET) with 18F-fluorodeoxyglucose (18F-FDG) for the staging of low-grade non-Hodgkin's lymphoma (NHL). Ann Oncol 2001; 12: 825-830.
11. Elstrom R, Guan L, Baker G et al. Utility of FDG-PET scanning in lymphoma by WHO classification. Blood 2003; 101: 3875-3876.
12. Schoder H, Noy A, Gonen M et al. Intensity of 18fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin's lymphoma. J Clin Oncol 2005; 23: 4643-4651.
13. Foo SS, Mitchell PL, Berlangieri SU et al. Positron emission tomography scanning in the assessment of patients with lymphoma. Intern Med J 2004; 34: 388-397.